clinical trial retatrutide for weight loss: Study shows 30% body weight loss Retatrutide Helped Adults With Diabetes

But more on that later

In a phase 2 clinical trial conducted on an obese population, over a 26-week period, patients who were administered a dose range of efinopegdutide from 5 mg to 10 mg experienced a weight reduction of up to 11.8%

This hormonal preservation is especially relevant for individuals with existing endocrine considerations, those prone to stress-related eating, or anyone seeking to avoid the systemic hormonal disruptions that often accompany aggressive fat loss interventions

These therapeutic indications represent opportunities for companies to leverage and explore new patient populations that will drive market growth